Document Detail


Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. The Benazepril Heart Failure Study Group.
MedLine Citation:
PMID:  1632402     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of the long-acting angiotensin-converting enzyme inhibitor benazepril hydrochloride on exercise tolerance and signs and symptoms of congestive heart failure (CHF) were evaluated in a double-blind, multicenter, placebo-controlled clinical trial. Patients with chronic New York Heart Association class II to IV symptoms of CHF and an ejection fraction by radionuclide scanning of less than or equal to 35% were randomized in a 2:1 ratio to treatment with ascending doses of oral benazepril (n = 114) or placebo (n = 58) once daily, while continuing to receive background therapy with digoxin and diuretics. After randomization, patients were evaluated clinically every 2 weeks during a 12-week, double-blind treatment period. Maximal exercise tolerance was measured before and at specified time points after randomization by graded treadmill exercise testing. At week 12, mean exercise time increased 95 +/- 12 (SEM) seconds in the group receiving benazepril, whereas the increase was 37 +/- 18 seconds in the group receiving placebo (p less than 0.01 for the difference between the groups). There was also greater improvement in overall clinical status and in the signs and symptoms of CHF in benazepril-treated patients than in control subjects. There were 3 deaths in placebo-treated patients and none in benazepril-treated patients (p less than 0.05); the overall incidence of adverse effects was identical in the 2 groups. Benazepril is a well-tolerated angiotensin-converting enzyme inhibitor that provides clinically important improvement in exercise tolerance and in signs and symptoms when given once daily to patients with CHF receiving background therapy with digoxin and a diuretic.
Authors:
H T Colfer; H S Ribner; A Gradman; C V Hughes; A Kapoor; J C Laidlaw
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  70     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1992 Aug 
Date Detail:
Created Date:  1992-08-20     Completed Date:  1992-08-20     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  354-8     Citation Subset:  AIM; IM    
Affiliation:
Cardiology Department, Burns Clinic Medical Center, Petoskey, Michigan 49770.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*,  adverse effects
Benzazepines / administration & dosage*,  adverse effects
Double-Blind Method
Drug Administration Schedule
Female
Heart Failure / drug therapy*,  physiopathology
Humans
Male
Middle Aged
Physical Endurance
Physical Exertion*
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Benzazepines; 86541-75-5/benazepril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description...
Next Document:  Comparison between New York Heart Association classification and peak oxygen consumption in the asse...